Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 18 studies | 58% ± 22% | |
ciliated cell | 12 studies | 34% ± 14% | |
adipocyte | 9 studies | 33% ± 13% | |
oligodendrocyte | 9 studies | 27% ± 11% | |
basal cell | 8 studies | 33% ± 15% | |
endothelial cell | 7 studies | 39% ± 20% | |
smooth muscle cell | 6 studies | 20% ± 5% | |
type II pneumocyte | 6 studies | 28% ± 9% | |
GABAergic neuron | 5 studies | 27% ± 9% | |
microglial cell | 5 studies | 25% ± 6% | |
epithelial cell | 5 studies | 33% ± 18% | |
oligodendrocyte precursor cell | 5 studies | 25% ± 8% | |
type I pneumocyte | 5 studies | 21% ± 5% | |
fibroblast | 4 studies | 25% ± 12% | |
cardiac muscle cell | 4 studies | 24% ± 2% | |
respiratory goblet cell | 4 studies | 37% ± 24% | |
club cell | 4 studies | 36% ± 16% | |
endothelial cell of lymphatic vessel | 4 studies | 22% ± 10% | |
pericyte | 4 studies | 23% ± 4% | |
interneuron | 3 studies | 22% ± 5% | |
myofibroblast cell | 3 studies | 22% ± 10% | |
Mueller cell | 3 studies | 27% ± 2% | |
glutamatergic neuron | 3 studies | 23% ± 2% | |
ependymal cell | 3 studies | 35% ± 16% | |
goblet cell | 3 studies | 35% ± 21% | |
transit amplifying cell | 3 studies | 36% ± 22% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 10 studies | 25% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 99% | 5974.99 | 243 / 245 | 100% | 121.69 | 501 / 502 |
brain | 99% | 6399.40 | 2619 / 2642 | 100% | 243.67 | 702 / 705 |
breast | 99% | 7079.31 | 456 / 459 | 95% | 74.03 | 1060 / 1118 |
ovary | 100% | 3606.00 | 180 / 180 | 89% | 63.23 | 381 / 430 |
stomach | 100% | 10366.22 | 359 / 359 | 83% | 34.38 | 237 / 286 |
lung | 99% | 3943.24 | 570 / 578 | 83% | 31.21 | 958 / 1155 |
pancreas | 100% | 9986.73 | 328 / 328 | 81% | 25.61 | 145 / 178 |
intestine | 100% | 11561.87 | 965 / 966 | 77% | 27.57 | 406 / 527 |
esophagus | 97% | 6460.47 | 1403 / 1445 | 69% | 27.93 | 126 / 183 |
uterus | 99% | 6314.92 | 169 / 170 | 49% | 28.92 | 227 / 459 |
thymus | 99% | 3916.85 | 648 / 653 | 39% | 11.04 | 234 / 605 |
liver | 93% | 2795.00 | 211 / 226 | 32% | 7.55 | 129 / 406 |
bladder | 81% | 2520.52 | 17 / 21 | 38% | 12.44 | 191 / 504 |
muscle | 100% | 4705.60 | 803 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 7952.30 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 4324.63 | 1192 / 1204 | 0% | 0 | 0 / 0 |
heart | 96% | 5700.14 | 827 / 861 | 0% | 0 | 0 / 0 |
skin | 78% | 3139.92 | 1414 / 1809 | 11% | 3.19 | 53 / 472 |
kidney | 25% | 437.26 | 22 / 89 | 35% | 7.91 | 315 / 901 |
tonsil | 0% | 0 | 0 / 0 | 44% | 16.85 | 20 / 45 |
lymph node | 0% | 0 | 0 / 0 | 31% | 6.80 | 9 / 29 |
spleen | 28% | 389.36 | 67 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 15% | 263.37 | 138 / 929 | 0% | 0 | 0 / 0 |
adrenal gland | 2% | 32.41 | 5 / 258 | 12% | 2.48 | 27 / 230 |
eye | 0% | 0 | 0 / 0 | 1% | 0.19 | 1 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007605 | Biological process | sensory perception of sound |
GO_0022405 | Biological process | hair cycle process |
GO_0060384 | Biological process | innervation |
GO_0032474 | Biological process | otolith morphogenesis |
GO_0005615 | Cellular component | extracellular space |
GO_0005886 | Cellular component | plasma membrane |
GO_0031012 | Cellular component | extracellular matrix |
GO_0005515 | Molecular function | protein binding |
Gene name | LRIG1 |
Protein name | Leucine-rich repeat protein LRIG1 Leucine-rich repeats and immunoglobulin-like domains protein 1 (LIG-1) |
Synonyms | LIG1 |
Description | FUNCTION: Acts as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation. . |
Accessions | ENST00000273261.8 [Q96JA1-1] Q5XWD3 ENST00000383703.3 [Q96JA1-2] Q96JA1 |